Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.60 |
| ▸ | PTK6 | Q13882 | 17/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 8/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15063040 | 0.87 | MAPKAPK5 (0.69) | MAPKAPK5PTK6AURKBAURKALCK | |
| SCHEMBL5575894 | 0.85 | PTK6 (0.57) | MAPKAPK5PTK6AURKBAURKALCK | |
| SCHEMBL1674071 | 0.82 | MAPKAPK5 (0.70) | MAPKAPK5PTK6AURKBAURKALCK | |
| SCHEMBL1674087 | 0.80 | MAPKAPK5 (0.60) | MAPKAPK5PTK6AURKBAURKALCK | |
| SCHEMBL10169565 | 0.79 | MAPKAPK5 (0.64) | MAPKAPK5PTK6AURKBAURKALCK | |
| SCHEMBL10169406 | 0.78 | MAPKAPK5 (0.57) | MAPKAPK5PTK6AURKBAURKALCK | |
| SCHEMBL5571621 | 0.78 | MAPKAPK5 (0.62) | MAPKAPK5PTK6AURKBAURKALCK | |
| SCHEMBL5573273 | 0.77 | MAPKAPK5 (0.64) | MAPKAPK5PTK6AURKBAURKALCK | |
| SCHEMBL14530726 | 0.76 | PTK6 (0.56) | MAPKAPK5PTK6AURKBAURKALCK | |
| SCHEMBL10169476 | 0.76 | AURKA (0.65) | MAPKAPK5PTK6AURKBAURKALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178530-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8178530-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8173656-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8173656-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-08 | — | — | US | disclosed |
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-09-08 | — | — | US | disclosed |
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-09-08 | — | — | US | disclosed |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-7893058-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-22 | — | — | US | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885PTK6 2026/4885AURKB 3575/4885 |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885PTK6 2026/4885AURKB 3575/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885PTK6 2026/4885AURKB 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.